- The shares of Ginkgo Bioworks (DNA) could potentially hit $6 according to analysts at Berenberg. These are the details.
Recently, Berenberg analysts assigned Ginkgo Bioworks a price target of $6 along with a “Buy” rating.
Berenberg analysts adjusted the rating while noting that Ginkgo is leveraging its platform to industrialize synthetic biology at scale across diverse end markets and has the only scaled horizontal platform in the space. And the analysts believe Ginkgo is well-positioned to disrupt cell programming across industries.
Price target: $81
Analyst firm: Morgan Stanley